메뉴 건너뛰기




Volumn 21, Issue 5, 1999, Pages 362-370

Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity

Author keywords

Abacavir; Antiproliferative; Antiretroviral; HIV 1; Mycophenolic acid; Synergy

Indexed keywords

ABACAVIR; GUANOSINE PHOSPHATE; INOSINE PHOSPHATE; MYCOPHENOLIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

EID: 0032841022     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199908150-00002     Document Type: Article
Times cited : (113)

References (43)
  • 1
    • 0028070503 scopus 로고
    • Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: Possible application in AIDS treatment
    • Blanchi V, Borella S, Calderazzo F, Ferraro P, Chieco Bianchi L, Reichard P. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci USA 1994;91:8403-7.
    • (1994) Proc Natl Acad Sci USA , vol.91 , pp. 8403-8407
    • Blanchi, V.1    Borella, S.2    Calderazzo, F.3    Ferraro, P.4    Chieco Bianchi, L.5    Reichard, P.6
  • 2
    • 0027976787 scopus 로고
    • Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools
    • Meyerhans A, Vartanian JP, Hultgren C, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994;68:535-40.
    • (1994) J Virol , vol.68 , pp. 535-540
    • Meyerhans, A.1    Vartanian, J.P.2    Hultgren, C.3
  • 3
    • 0027377963 scopus 로고
    • Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
    • Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 8925-8928
    • Gao, W.Y.1    Cara, A.2    Gallo, R.C.3    Lori, F.4
  • 4
    • 0027948936 scopus 로고
    • Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
    • Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-5.
    • (1994) Science , vol.266 , pp. 801-805
    • Lori, F.1    Malykh, A.2    Cara, A.3
  • 5
    • 0028019710 scopus 로고
    • Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides
    • Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-72.
    • (1994) Mol Pharmacol , vol.46 , pp. 767-772
    • Gao, W.Y.1    Johns, D.G.2    Mitsuya, H.3
  • 6
    • 0028116945 scopus 로고
    • Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes
    • Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-21.
    • (1994) Proc Natl Acad Sci USA , vol.91 , pp. 11017-11021
    • Malley, S.D.1    Grange, J.M.2    Hamedi-Sangsari, F.3    Vila, J.R.4
  • 7
    • 0029086336 scopus 로고
    • Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus
    • Gao WY, Johns DG, Chokekuchai S, Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995;92:8333-7.
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 8333-8337
    • Gao, W.Y.1    Johns, D.G.2    Chokekuchai, S.3    Mitsuya, H.4
  • 8
    • 0030831543 scopus 로고    scopus 로고
    • Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
    • Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-9.
    • (1997) AIDS Res Hum Retroviruses , vol.13 , pp. 1403-1409
    • Lori, F.1    Malykh, A.G.2    Foli, A.3
  • 9
    • 0031693813 scopus 로고    scopus 로고
    • Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine
    • Luzzati R, Di Perri G, Fendt D, Ramarli D, Broccali G, Concia E. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine. J Antimicrob Chemother 1998;42:565-6.
    • (1998) J Antimicrob Chemother , vol.42 , pp. 565-566
    • Luzzati, R.1    Di Perri, G.2    Fendt, D.3    Ramarli, D.4    Broccali, G.5    Concia, E.6
  • 10
    • 0029086733 scopus 로고
    • Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals
    • Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10: 36-40.
    • (1995) J Acquir Immune Defic Syndr Hum Retrovirol , vol.10 , pp. 36-40
    • Biron, F.1    Lucht, F.2    Peyramond, D.3
  • 11
    • 18544411156 scopus 로고    scopus 로고
    • Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals
    • Biron F, Lucht F, Peyramond D, et al. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res 1996;29:111-3.
    • (1996) Antiviral Res , vol.29 , pp. 111-113
    • Biron, F.1    Lucht, F.2    Peyramond, D.3
  • 12
    • 0030956535 scopus 로고    scopus 로고
    • A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080
    • Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-6.
    • (1997) J Infect Dis , vol.175 , pp. 801-806
    • Montaner, J.S.1    Zala, C.2    Conway, B.3
  • 13
    • 0029933819 scopus 로고    scopus 로고
    • Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection
    • Vila J, Biron F, Nugier F, Vallet T, Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996;348:203-4.
    • (1996) Lancet , vol.348 , pp. 203-204
    • Vila, J.1    Biron, F.2    Nugier, F.3    Vallet, T.4
  • 14
    • 0030055872 scopus 로고    scopus 로고
    • Treatment of human immunodeficiency virus infection with hydroxyurea: Virologie and clinical evaluation
    • Giacca M, Zanussi S, Comar M, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologie and clinical evaluation. J Infect Dis 1996;174:204-9.
    • (1996) J Infect Dis , vol.174 , pp. 204-209
    • Giacca, M.1    Zanussi, S.2    Comar, M.3
  • 15
    • 7144257857 scopus 로고    scopus 로고
    • A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
    • Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12: F71-7.
    • (1998) AIDS , vol.12
    • Rutschmann, O.T.1    Opravil, M.2    Iten, A.3
  • 16
    • 0032524983 scopus 로고    scopus 로고
    • Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus
    • Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998;55:1551-6.
    • (1998) Biochem Pharmacol , vol.55 , pp. 1551-1556
    • Johns, D.G.1    Gao, W.Y.2
  • 17
    • 0032504930 scopus 로고    scopus 로고
    • Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
    • De Boer RJ, Boucher CA, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-70.
    • (1998) AIDS , vol.12 , pp. 1567-1570
    • De Boer, R.J.1    Boucher, C.A.2    Perelson, A.S.3
  • 18
    • 0003290066 scopus 로고    scopus 로고
    • Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy naive adults at 24 weeks
    • Chicago
    • Staszeweski S, Keiser P, Gathe J, et al. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy naive adults at 24 weeks [abstract 20]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
    • (1999) 6th Conference on Retroviruses and Opportunistic Infections
    • Staszeweski, S.1    Keiser, P.2    Gathe, J.3
  • 19
    • 0025847662 scopus 로고
    • In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443
    • Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991;23(Suppl 2): 10-4.
    • (1991) Transplant Proc , vol.23 , Issue.SUPPL. 2 , pp. 10-14
    • Allison, A.C.1    Almquist, S.J.2    Muller, C.D.3    Eugui, E.M.4
  • 21
    • 0027717956 scopus 로고
    • Characterization of human type I and type II IMP dehydrogenases
    • Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268: 27286-90.
    • (1993) J Biol Chem , vol.268 , pp. 27286-27290
    • Carr, S.F.1    Papp, E.2    Wu, J.C.3    Natsumeda, Y.4
  • 22
    • 0029116425 scopus 로고
    • Polymerase substrate depletion: A novel strategy for inhibiting the replication of the human immunodeficiency virus
    • Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-60.
    • (1995) Virology , vol.211 , pp. 554-560
    • Ichimura, H.1    Levy, J.A.2
  • 23
    • 0031952851 scopus 로고    scopus 로고
    • The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
    • Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998;42:216-22.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 216-222
    • Neyts, J.1    Andrei, G.2    De Clercq, E.3
  • 24
    • 0031758701 scopus 로고    scopus 로고
    • The antiherpesvirus activity of H2G is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil
    • Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother 1998;42: 3285-9.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 3285-3289
    • Neyts, J.1    Andrei, G.2    De Clercq, E.3
  • 25
    • 0021237243 scopus 로고
    • Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre AIDS
    • Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre AIDS. Science 1984; 224:497.
    • (1984) Science , vol.224 , pp. 497
    • Popovic, M.1    Sarngadharan, M.G.2    Read, E.3    Gallo, R.C.4
  • 26
    • 0023681241 scopus 로고
    • Distinct biological and serological properties of human immunodeficiency viruses from the brain
    • Chenge-Mayer C, Levy JA. Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 1988;23:S58.
    • (1988) Ann Neurol , vol.23
    • Chenge-Mayer, C.1    Levy, J.A.2
  • 27
    • 0027409698 scopus 로고
    • Characterization of human immunodeficiency viruses resistant to oxathiolance-cytosine nucleosides
    • Schinazy RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolance-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875.
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 875
    • Schinazy, R.F.1    Lloyd R.M., Jr.2    Nguyen, M.H.3
  • 28
    • 0344034052 scopus 로고
    • NIH Pub No. 94 3828. Bethesda, MD: National Institutes of Health
    • ACTG virology manual, NIH Pub No. 94 3828. Bethesda, MD: National Institutes of Health, 1994.
    • (1994) ACTG Virology Manual
  • 29
    • 0022404296 scopus 로고
    • Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in plaque assay
    • Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in plaque assay. Science 1985;229:563.
    • (1985) Science , vol.229 , pp. 563
    • Harada, S.1    Koyanagi, Y.2    Yamamoto, N.3
  • 31
    • 0029036955 scopus 로고
    • The search for synergy: A critical review from a response surface perspective
    • Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-85.
    • (1995) Pharmacol Rev , vol.47 , pp. 331-385
    • Greco, W.R.1    Bravo, G.2    Parsons, J.C.3
  • 33
    • 0003910309 scopus 로고    scopus 로고
    • Research Triangle Park, NC: Glaxo Wellcome, Inc.
    • Ziagen package insert. Research Triangle Park, NC: Glaxo Wellcome, Inc., 1999.
    • (1999) Ziagen Package Insert
  • 34
    • 0344465148 scopus 로고    scopus 로고
    • Nutley, NJ: Roche Laboratories
    • Cellcept package insert. Nutley, NJ: Roche Laboratories, 1998.
    • (1998) Cellcept Package Insert
  • 35
    • 0029917782 scopus 로고    scopus 로고
    • Pharmacokinetics of mycophenolate mofetil (RS61443): A short review
    • Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28:925-9.
    • (1996) Transplant Proc , vol.28 , pp. 925-929
    • Bullingham, R.E.S.1    Nicholls, A.2    Hale, M.3
  • 36
    • 0031596029 scopus 로고    scopus 로고
    • Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
    • Drusano GL, D'Argenio DZ, Symonds W, et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998;42:2153-9.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 2153-2159
    • Drusano, G.L.1    D'Argenio, D.Z.2    Symonds, W.3
  • 37
    • 0030945276 scopus 로고    scopus 로고
    • Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
    • Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997;41:1094-8.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1094-1098
    • Tisdale, M.1    Alnadaf, T.2    Cousens, D.3
  • 38
    • 0000498539 scopus 로고    scopus 로고
    • Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history
    • Chicago
    • Lanier R, Ait-Khaled M, Madison S, et al. Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history [abstract 134]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
    • (1999) 6th Conference on Retroviruses and Opportunistic Infections
    • Lanier, R.1    Ait-Khaled, M.2    Madison, S.3
  • 39
    • 0023122258 scopus 로고
    • Ribavirin antagonizes the effect of azidothymidine on HIV replication
    • Vogt M W, Hartshorrn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9.
    • (1987) Science , vol.235 , pp. 1376-1379
    • Vogt, M.W.1    Hartshorrn, K.L.2    Furman, P.A.3
  • 40
    • 0023636684 scopus 로고
    • Ribavirin antagonizes inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency vi-rus in vitro
    • Baba M, Pauwels R, Balzarini J, Herdewijn P, DeClercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency vi-rus in vitro. Antimicrob Agents Chemother 1987;31:1613-17.
    • (1987) Antimicrob Agents Chemother , vol.31 , pp. 1613-1617
    • Baba, M.1    Pauwels, R.2    Balzarini, J.3    Herdewijn, P.4    DeClercq, E.5    Desmyter, J.6
  • 41
    • 0025773889 scopus 로고
    • Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine
    • Hartman NR, Ahluwalia GS, Cooney DA, et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol Pharmacol 1991;40:118-24.
    • (1991) Mol Pharmacol , vol.40 , pp. 118-124
    • Hartman, N.R.1    Ahluwalia, G.S.2    Cooney, D.A.3
  • 43
    • 0027094084 scopus 로고
    • Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism
    • Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1994;41:671-676.
    • (1994) Mol Pharmacol , vol.41 , pp. 671-676
    • Dayton, J.S.1    Turka, L.A.2    Thompson, C.B.3    Mitchell, B.S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.